AIA
TEVA icon

Affinity Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Affinity Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,923
Closed -$337K – 157
2025
Q1 		$337K Buy
21,923
+3,356
+18% +$59.9K 0.27% 102
2024
Q4 		$409K Buy
18,567
+2,376
+15% +$43.2K 0.34% 92
2024
Q3 		$292K Hold
16,191
– – 0.2% 114
2024
Q2 		$263K Sell
16,191
-8,626
-35% -$133K 0.2% 112
2024
Q1 		$350K Hold
24,817
– – 0.26% 101
2023
Q4 		$259K Buy
24,817
+636
+3% +$5.94K 0.18% 158
2023
Q3 		$247K Sell
24,181
-7,336
-23% -$68.3K 0.16% 169
2023
Q2 		$237K Buy
+31,517
New +$256K 0.14% 179

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Affinity Investment Advisors's TEVA Position: Q2 2025 in Review

Affinity Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 21,923 shares — an estimated $337K sold.

Affinity Investment Advisors first reported a position in TEVA in Q2 2023 and held it in 8 quarters. The position peaked at $409K in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Affinity Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Affinity Investment Advisors sold 21,923 Teva Pharmaceuticals shares in Q2 2025, an estimated $337K.
  • Affinity Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Affinity Investment Advisors's Teva Pharmaceuticals position peaked at $409K in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Affinity Investment Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.